ArticleSAGE open medicine2026
Capsaicin attenuates high-fat diet-induced impairment of B-cell immunity.
Article in SAGE open medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Obesity contributes to immune system dysregulation, thereby increasing the risk of developing numerous diseases. Dietary capsaicin (CAP) has been demonstrated to mitigate obesity, while its impact on B cell immunity during obesity remains unexplored. This study aimed to investigate the restorative effect of CAP on B cells deficiency in obese mice, and explore the underlying mechanisms. Methods: C57BL/6J mice were fed a standard chow diet or a high-fat diet (HFD), and HFD-fed mice were orally administered CAP. Flow cytometry was employed to evaluate the effect of CAP on B cell function in HFD mice. RNA-seq, RT-qPCR, etc, were utilized to elucidate the underlying mechanisms. Results: CAP not only ameliorated HFD-induced metabolic abnormalities, but also reversed the HFD-associated reduction in the population of intestinal germinal center (GC) and IgA Conclusions: CAP alleviates insulin resistance and restores the impaired GC B cell in obese mice. These findings highlight a mechanism underlying the anti-obesity effect of CAP and lay a foundation for its clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.